Questions Passed as Orders for Returns  With regard to healthcare in Canada: (a) what is specifically included under universal health services; (b) has the scope of services included under universal health services changed since first implemented and, if so, (i) what are the changes, (ii) on what dates did these changes take place; (c) what are the specific services that are (i) funded publicly, (ii) not fully publicly funded; (d) what was the annual total health spending in Canada, broken down by year from 2010 to present; (e) what was the private total health spending in Canada since 2010 to present; (f) what, if any, publicly insured services are being offered for out-of-pocket pay, and, if relevant, what is the annual spending since 2010; (g) what was the annual per capita spending on health since 2010, and how does per capita spending compare to that of Organisation for Economic Co-operation and Development (OECD) countries; (h) what was the private annual per capita spending on health since 2010; (i) what was the investment in homecare since 2010, and, for each investment, (i) how many more people were served, (ii) what was the average wait time from approval to service delivery, (iii) has the wait time from approval to service delivery changed; (j) what, if any, mechanisms have existed to hold provinces and territories accountable on how they spend the health transfer, and, if relevant, what is (i) the accountability mechanism, (ii) the date; (k) for each province and territory, what is the annual funding compared to the age-adjusted population growth since 2010; (l) for each province and territory, what is specifically included under universal health services; (m) for each province and territory, has the scope of services changed since universal health services were first implemented, and, if so, what are (i) the changes, (ii) the dates of the changes; (n) for each province and territory, what are the specific services that are (i) funded publicly, (ii) not fully publicly funded; (o) for each province and territory, what (i) is the percentage increase in healthcare service costs since the last health transfer, (ii) is the new negotiated health transfer, (iii) new services will the transfer buy for Canadians; (p) where does Canada rank with respect to amenable mortality among comparator countries, and (i) where have there been improvements, (ii) where specifically has there been a lack of improvement; (q) what does Canada spend on pharmaceuticals, and how does Canada rank among the OECD; (r) what are all of the pan-Canadian health benchmarks, and what is the target for each benchmark; (s) for each benchmark, what is the percentage of patients receiving care within each of the pan-Canadian benchmarks, broken down by province and territory; (t) what is the percentage of patients receiving care within the benchmarks for (i) cataract removal, (ii) hip fracture repair, (iii) hip replacement, (iv) knee replacement, broken down by province and territory; (u) how does Canada rank with respect to service wait times for comparator countries, specifically to (i) see a general practitioner, (ii) see a specialist, (iii) be treated in an emergency department, (iv) receive advanced diagnostics, (v) receive elected surgical care; (v) what is the average wait time to (i) see a general practitioner, (ii) see a specialist, (iii) be treated in an emergency department, (iv) receive advanced diagnostics, (v) receive elected surgical care, in each province and territory; (w) how many people left an emergency department in 2022-23 without ever having been seen, broken down by province and territory; (x) what is the health and social services sector vacancy rate in each province and territory; (y) what is the physician supply gap in each province and territory and how does Canada rank against comparator countries; (z) in each province and territory, (i) what is the vacancy rate for nurses, (ii) what discipline has the highest vacancy rate; (aa) broken down by province and territory, what percentage of Canadians lack a primary care provider; (bb) how does Canada rank on inequality in healthcare by income compared to other countries; (cc) what groups of Canadians have difficulty accessing primary care, and, for each group identified, how (i) is access to a general practitioner, (ii) is prescription use, (iii) is access to a specialist, (iv) are diagnostics, (v) is treatment, (vi) is morbidity, (vii) is mortality, impacted; (dd) in each province and territory, what percentage of cost is covered for prescription drugs outside (i) the hospital, (ii) homecare, (iii) non-physician mental health care; (ee) what percentage of income do Canadians in the lowest income quintile spend on their healthcare; (ff) what percentage of income do Canadians in the highest income quintile spend on their healthcare; (gg) broken down by province and territory, (i) how many more people were served with respect to long-term care since 2010 by each federal health transfer, (ii) what was the average wait time from approval to service delivery, (iii) has the wait time from approval to service delivery changed; (hh) broken down by province and territory, what percentage of hospital-bed days is designated to those awaiting long-term care; (ii) how does Canada rank with respect to comparator countries on (i) health outcome measures, (ii) patient-reported experience; (jj) what specific data is collected at the federal level on medical errors, including, but not limited to, (i) patient harm, (ii) a foreign body left in after a procedure, (iii) obstetric trauma, (iv) postoperative pulmonary embolism after a hip replacement, (v) postoperative pulmonary embolism after a knee replacement, and how does this data compare internationally; (kk) what specific data is collected at the provincial and territorial level on (i) medical errors, (ii) patient harm; (ll) how does Canada rank with respect to comparator countries on (i) dental coverage, (ii) non-physician mental health care, (iii) vision?

Questions Passed as Orders for Returns  With regard to women’s health in Canada and clinical research funded by the Canadian Institutes of Health Research (CIHR): (a) how much did the government invest in women’s health annually, from 2010 to present, and specifically, for the same time period, how much was invested in (i) aging, (ii) cardiovascular conditions, (iii) neurological conditions, and how did these investments compare to that of the United States; (b) how much did the CIHR invest in women’s health annually, from 2010 to present, and specifically, for the same time period, how much was invested in (i) aging, (ii) cardiovascular conditions, (iii) neurological conditions, and how did these investments compare to that of the National Institutes of Health (NIH); (c) broken down by all common female-specific conditions, including, but not limited to, endometriosis, fibroid tumours, pelvic inflammatory disease, and polycystic ovary syndrome, (i) what are the number of women impacted, (ii) what is the cost to the healthcare system, (iii) what are the effective diagnostics, if any, (iv) what are the effective treatments, if any, (v) is the condition under-researched, (vi) what is the annual investment since 2010, (vii) how does investment compare to that of the United States, (viii) what is the annual investment by CIHR since 2010, (ix) how does investment compare to that of the NIH; (d) what annual investment has the government made since 2010 in (i) fertility, (ii) pregnancy, (iii) maternal health, (iv) reducing maternal morbidity and mortality, (v) breastfeeding, and how does investment compare to that of the United States; (e) what annual investment has the CIHR made since 2010 in (i) fertility, (ii) pregnancy, (iii) maternal health, (iv) reducing maternal morbidity and mortality, (v) breastfeeding, and how does investment compare to that of the NIH; (f) broken down by all specific female cancers including, but not limited to, cervical cancer, ovarian cancer, uterine cancer, vaginal cancer, (i) what is the number of women impacted, (ii) what is the cost to the healthcare system, (iii) what are the effective diagnostics, if any, (iv) what are the effective treatments, if any, (v) what is the average cancer stage at diagnosis, (vi) what is the annual investment by the government since 2010, (vii) how does investment compare to that of the United States, (viii) what is the annual investment by the CIHR since 2010, (ix) how does the investment compare with that of the NIH; (g) broken down by all specific conditions that disproportionately affect women including, but not limited to, autoimmune diseases, chronic pain, Alzheimer’s disease, osteoporosis, and specific cancers, (i) what is the number of women affected, (ii) what is the cost to the health care system, (iii) what is the annual investment by the government since 2010, (iv) how does the investment compare to that of the United States, (v) what is the investment in research by the CIHR annually since 2010, (vi) how does the investment compare to that of the NIH; (h) what percentage of CIHR’s budget is invested in the gender and health institute, and how does this percentage compare to each of the remaining institutes; (i) does CIHR have a policy regarding the sex of animals used in pre-clinical research, and, if so, what are the details of the policy, including the date it came into effect; (j) does all CIHR-supported pre-clinical research require the use of female and male animals; (k) what percentage of CIHR’s pre-clinical research uses female animals, and how is that percentage measured; (l) what percentage of CIHR’s pre-clinical research reports on the sex of animal subjects, and how is it measured; (m) is it mandated that all CIHR-supported clinical research include women, and, if so, what (i) is the date of the mandate, (ii) is the policy, (iii) are the exceptions, (iv) are any requirements for analysis to include sex, gender, and intersectionality, (v) are any requirements for reporting on sex, gender, and intersectionality; (n) how specifically does CIHR track whether clinical research includes women, what are all questions on grant applications, and what questions and formulae are used to calculate the percentage of CIHR-supported clinical research involving women; (o) what percentage of CIHR-supported clinical research involves women; (p) what percentage of CIHR-funded research examines (i) sex, (ii) gender, (iii) intersectionality, and how are these measured; (q) what specific policies has CIHR put in place to ensure women of all ages and backgrounds are included in clinical research populations; (r) does CIHR provide support for research specifically focused on populations of women historically (i) under-represented, (ii) under-researched, (iii) under-reported, in clinical research, and, if so, what specific investment is made for each?

Questions Passed as Orders for Returns  With regard to cancer in Canada: (a) what are the top 10 cancers annually since 2010, broken down by province and territory, and, for each cancer, what is the (i) morbidity rate, (ii) mortality rate, (iii) five-year net survival rate; (b) how do the rates in (a)(i), (a)(ii), (a)(iii) compare to the United States; (c) for the rates in (a)(i) and (a)(ii), what is the (i) number of people affected, (ii) cost to the health care system, (iii) total investment compared to the United States; (d) are there any types of cancer on the rise in Canada, and, if so, what are they, broken down by province and territory; (e) what percentage of new patients are offered a diagnostic molecular test in Canada; (f) what percentage of patients are offered a clinical trial in Canada; (g) what percentage of patients are enrolled in a clinical trial in Canada; (h) how many clinical trials have been initiated in Canada annually since 2010; (i) what cancer prevention programs, by cancer type, are funded by the government; (j) how much has the government invested since 2010 in the top 10 cancers, broken down by (i) cancer diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (k) how much has the government annually invested since 2010 in pediatric cancer, broken down by (i) diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (l) how much has the government invested since 2010 in rare cancer, broken down by (i) diagnosis, (ii) treatment, (iii) research, (iv) prevention, (v) federal transfers, and the specific amount, (vi) direct investment in cancer programs, and the specific amount, (vii) research funding, and how does the total investment compare to the United States; (m) does the Scientific Advisory Committee on Oncology Therapies still exist, and, if so, (i) what is its membership, (ii) when did it last meet, (iii) what was on the agenda of all meetings since 2019; (n) what is the average approval time for phased clinical trials for the top 10 cancers in Canada, broken down by (i) phase I clinical trials, (ii) phase II clinical trials, (iii) phase III clinical trials, (iv) phase IV clinical trials, and how do the approval times in (i), (ii), (iii) and (iv) compare to the United States; (o) what percentage of Canadian children undergoing cancer treatment have access to a clinical trial; (p) what is the average approval time for phased clinical trials for rare cancers in Canada, broken down by (i) phase I clinical trials, (ii) phase II clinical trials, (iii) phase III clinical trials, (iv) phase IV clinical trials, and how do the approval times in (i), (ii), (iii) and (iv) compare to the United States; (q) how many new cancer treatments has Health Canada (HC) approved since 2010 and what percentage have been precision treatments; (r) what are all cancer drugs approved in Canada, and the dates of approval since 2010, broken down by the (i) date the drug was approved in the United States, (ii) provinces and territories where the drug is available, (iii) provinces and territories covering the entire drug cost, (iv) provinces and territories requiring patient payment, (v) additional cost per treatment; (s) how many new cancer treatments has HC approved since 2010 for the top 10 cancers, what percentage have been precision treatments and how do the approval rates and times compare to those in the United States; (t) how many new pediatric cancer treatments has HC approved since 2010 and what percentage have been precision treatments; (u) how many new rare cancer treatments has HC approved since 2010 and what percentage have been precision treatments; (v) on what date was the special access program for drugs first put in place, (i) how many applications have been made for chemotherapy drugs since its creation, (ii) how many times have approvals been made for chemotherapy drugs since its creation, (iii) what is the average approval wait time for a chemotherapy drug, (iv) is there a process for re-application, and, if so, what is the average approval time for re-application of a chemotherapy drug; (w) what are the top 10 pediatric cancers since 2010 annually, broken down by province and territory, and, for each cancer, what is the (i) morbidity rate, (ii) mortality rate, (iii) five-year survival rate by stage, (iv) cost to the healthcare system; (x) for each rate in (w)(i) and (ii), what is the number of people affected; (y) what is the list of all rare cancers in Canada, how many people are affected by rare cancers, and what investments has the government made in their research; (z) what is the process for a clinician to access off-label chemotherapy options for a patient with a rare cancer, including (i) the average approval time, (ii) the re-approval process, and, if any, the average re-approval wait time, (iii) the approval success rate for application, (iv) if relevant, the approval success rate for re-application, (v) the approval success rate when a drug is already approved for use in another country; (aa) what is the average time to diagnosis for each of the (i) top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and what is the average cancer stage at diagnosis and the cost to the healthcare system, since 2010, broken down by province and territory; (bb) what was the average time to diagnosis for each of the (i) top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and what is the average cancer stage at diagnosis and the cost to the healthcare system, broken down by province and territory, and annually from 2019 to 2023; (cc) how many people had to seek diagnosis outside of Canada due to either wait time or lack of diagnostic technology or procedure, and what was the cost to the healthcare system, broken down by province and territory annually since 2010; (dd) how many people had to seek treatment outside of Canada due to either wait time or lack of treatment that was available elsewhere, and what was the cost to the healthcare system, broken down by province and territory annually since 2010; (ee) how many people could not get a recommended chemotherapy because (i) they did not have health insurance, (ii) their health coverage did not cover a chemotherapy drug, (iii) their insurance covered only part of the drug cost, broken down by province and territory; (ff) broken down by province and territory, how many times has the federal special access program been accessed since its inception, (i) how many approvals have been made since its inception, (ii) what is the average approval time, (iii) is there a process for re-application, and, if so, what is the average approval time for re-application; (gg) what has each government invested in cancer treatment since 2010, broken down by province and territory; and (hh) how much has the Canadian Institutes of Health Research invested annually in cancer research since 2010, and specifically what has been invested in (i) the top 10 cancers, (ii) pediatric cancers, (iii) rare cancers, and how does this annual total investment compare to the United States?

Questions Passed as Orders for Returns  With regard to international charters, conferences, consensus statements, declarations, policy, and national reports regarding sport and abuse, discrimination, and harassment: (a) following the UNESCO International Charter of Physical Education and Sport in 1978, and with respect to the statement that “sport practiced by all must be protected against any abuse”, what, if any, (i) actions were taken against abuse in sport, (ii) new requirements were adopted as a result of the Charter with respect to “appropriate qualifications”, “training”, and “further training” for each of those in administration, coaching, teaching, and volunteering, and on which dates between 1978 and 1988; (b) following the UNESCO International Charter of Physical Education and Sport in 1978, and with respect to the statement that “it is crucial that the fight against doping should win the support of national and international authorities”, what, if any, actions did Canada take, and on which dates between 1978 and 1988; (c) following the 1990 release of the Commission of Inquiry into the Use of Drugs and Banned Practices Intended to Increase Athletic Performance and with respect to the recommendation “that individuals and organizations in receipt of government funding meet the ethical standards as well as the performance standards required for funding”, what actions, if any, did Canada take in response to the recommendation for individuals and organizations, and on which dates; (d) following the 1990 release of the Commission of Inquiry into the Use of Drugs and Banned Practices Intended to Increase Athletic Performance, and with respect to the recommendation “that those involved in the health, care, and training of athletes are qualified to be so ethically as well as technically”, what actions, if any, did Canada take regarding ethical qualifications for all those involved in the health, care, and training of athletes, and on which dates; (e) following the 1990 release of the Commission of Inquiry into the Use of Drugs and Banned Practices Intended to Increase Athletic Performance, and with respect to the recommendation that “the measure of success of government funding be linked not to medal count, but to the degree to which it has met the social, educational, and national goals of government for sport”, what actions, if any, did Canada take to (i) disentangle medal count from funding, (ii) tie medal count to funding, and on which dates; (f) following the International Olympic Committee’s adoption of a Consensus Statement on Sexual Harassment and Abuse in Sport in 2007, what actions, if any, has Canada undertaken with respect to (i) developing “policies and procedures for the prevention of sexual harassment and abuse”, (ii) monitoring “the implementation of these policies and procedures”, (iii) evaluating “the impact of these policies in identifying and reducing sexual harassment and abuse”, (iv) developing “an education and training program on sexual harassment and abuse in their sport(s)”, (v) fostering “strong partnerships with parents in the prevention of sexual harassment and abuse”, (vi) promoting and supporting scientific research on these issues, and on which dates; (g) did any representatives of Canada attend the 5th International Conference of Ministers and Senior Officials Responsible for Physical Education and Sport in 2013, and, if so, what were the names of positions of all those who attended; (h) following the 2013 Declaration of Berlin, what actions, if any, has Canada taken with respect to Article 1.4 of the Declaration “recognizing that an inclusive environment free of violence, sexual harassment, racism and other forms of discrimination is fundamental to quality physical education and sport”, and on which dates; (i) following the revised International Charter of Physical Education, Physical Activity and Sport in 2015, what actions, if any, has Canada taken with respect to (i) “safety and management of risk”, (ii) Article 10.1 which states that, “All forms of physical education, physical activity and sport must be protected from abuse”, (iii) any identified harms, (iv) “bullying”, (v) “deprivation of education”, (vi) “discrimination”, (vii) “excessive training of children”, (viii) “homophobia”, (ix) “racism”, (x) “sexual exploitation”, (xi) “violence”, (xii) “potential risks, especially for children, of dangerous or inappropriate training methods and competition, and psychological pressures of any kind”, and on which dates were these actions taken; (j) following the issue of the Policy on Non-Accidental Violence and Abuse in Sport of the International Paralympic Committee in 2016, what actions, if any, were taken by Canada with respect to violations of human rights, including, but not limited to, (i) “bullying and emotional abuse”, (ii) “child exploitation”, (iii) “hazing”, (iv) “neglect”, (v) “physical abuse”, (vi) “sexual abuse and assault”, and on which dates; (k) did Canada attend the Sixth International Conference of Ministers and Senior Officials Responsible for Physical Education and Sport in 2017, and, if so, what were the positions of all those who attended; and (l) following the Kazan Action Plan, what actions, if any, did Canada undertake with respect to (i) “protecting the integrity of sport”, (ii) “III.1 Safeguard athletes, spectators, workers and other groups involved”, (iii) “III.2 Protect children, youth and other vulnerable groups”, and on which dates?

Questions Passed as Orders for Returns  With regard to athlete abuse, discrimination, and harassment in sport in Canada: (a) what are all the groups of athletes under federal jurisdiction; (b) are athletes who are carded under the Athlete Assistance Program considered protected under federal jurisdiction; (c) how many athletes are currently carded, broken down by sport; (d) how many athletes have been carded, broken down by sport since any form of carding began; (e) has the government ever undertaken a large-scale survey of athletes under its jurisdiction or protection, while protecting their privacy, on athlete abuse, discrimination, and harassment; (f) has the government ever taken such a survey of current carded athletes, while protecting their privacy; (g) has the government ever undertaken such a survey of past carded athletes, while protecting their privacy; (h) if the answer to (e), (f) or (g) is affirmative, what are the details of the survey, including (i) the dates, (ii) the questions, (iii) the results, (iv) any changes to protecting athlete health, safety, and wellbeing as a result; (i) does each national sport organization (NSO) have a formal policy to address (i) abuse, (ii) discrimination, (iii) harassment; (j) which NSOs do not have a policy; (k) how often does Sport Canada review such policies as in (i)(i) to (i)(iii), and has any policy ever been required to be strengthened, and, if so, how and when; (l) does each NSO have an independent third party to address abuse, discrimination, and harassment; (m) which NSOs do not have an independent third party; (n) what are the minimum requirements for a third party; (o) what oversight, if any, does Sport Canada provide; (p) broken down by NSO, for each one, is annual mandatory training on (i) abuse, (ii) discrimination, (iii) harassment, taking place; (q) broken down by NSO, for each one, how does Sport Canada track what annual training is taking place; (r) broken down by NSO, for each one, how many athletes, coaches, trainers, medical personnel, judges or referees, parents, and volunteers have gone through such training, broken down by year since April 2020; (s) how many incidents of abuse, discrimination, and harassment, broken down by sport, have been reported to Sport Canada, broken down by year since June 2018; (t) of the incidents in (s), how many of them (i) involved a team, (ii) involved a coach or trainer, (iii) involved medical personnel, (iv) involved a judge or referee, (v) involved another athlete, (vi) involved anyone else in a position of power, (vii) were considered sufficiently serious to withhold funding; (u) in the context of withholding funding, how is “sufficiently serious” defined; (v) how many cases were transferred to the Office of the Sport Integrity Commissioner (OSIC); (w) what is the current backlog of cases broken down by sport at the OSIC; (x) how many cases at the OSIC have been effectively resolved; (y) what is, in detail, the current reporting mechanism for reporting an incident of abuse, discrimination or harassment to the appropriate channels at the federal level, and what are all the appropriate channels; (z) since June 2018, broken down by sport, how many coaches, trainers, medical personnel, judges or referees, or any other person in a position of power have been (i) suspended, (ii) removed from the sport system, (iii) referred to the police; (aa) what mechanisms have been put in place to ensure that anyone (i) suspended, (ii) removed, (iii) criminally convicted, cannot work, volunteer or cross jurisdictions to work or volunteer with athletes or children in Canada and internationally; (bb) what work, if any, has been undertaken on any form of registry of offenders to protect athletes and children, and what were the steps taken; (cc) since 2018, how much funding has the government invested in safe sport, and, for each, what were the dates and investments; (dd) how much funding has each NSO invested in safe sport, and what areas of safe sport has each NSO invested in; (ee) are U Sports athletes protected under federal jurisdiction; (ff) what governments have jurisdiction over U Sports; (gg) who has jurisdiction if an athlete is both a university athlete and a carded athlete; (hh) are Canadian Collegiate Athletic Association athletes protected under federal jurisdiction; (ii) what governments have jurisdiction over Canadian Collegiate Athletic Association; and (jj) who has jurisdiction if an athlete is both a college athlete and a carded athlete?

Questions Passed as Orders for Returns  With regard to the Canadian sport helpline and the abuse-free sport helpline: (a) in what month and year was the service first launched; (b) what are the details of the program’s financing, including (i) the cost to administer the program annually, (ii) whether there have been any changes to the finances since its inception, (iii) the dates of any such changes; (c) what is the size of the current team that leads the program, and what are the details of the team that leads the program including the name of all positions of the current team; (d) how many days a week is the service available, and (i) what are the specific times when the service is available for each day, (ii) how many operators are available during these times, (iii) what training do each of the operators have; (e) how is the existence of the service communicated to athletes, and who is responsible for doing so; (f) broken down annually and by sport, while protecting privacy of all callers, how many calls have been logged yearly since 2019; (g) broken down annually and by sport, while protecting the privacy of all callers, how many calls provided advice on (i) a complaints process, (ii) how to seek help from the Office of the Sport Integrity Commissioner, (iii) how to seek help from a national sport organization, (iv) how to seek help from a provincial or territorial sport organization, (v) how to seek help from a lawyer, (vi) how to seek help from the police, (vii) on any other matter, including the full range of issues that athletes, parents, witnesses, and any callers were concerned about; and (h) who has oversight of data from the helpline, and, while protecting privacy of all callers, what analysis, if any, has been undertaken on the data and (i) on what timescales, (ii) have any such analyses been used to inform further action to protect athletes and young people, and, if so, what are the details of each instance?

Questions Passed as Orders for Returns  With regard to the Red Deer Declaration signed in 2019: (a) how many federal, provincial and territorial sport ministerial meetings have been held, and, for each meeting, what were the details, including (i) the date, (ii) the agenda, (iii) whether safety and integrity in sport were on the agenda, (iv) what specifically was discussed regarding safety in sport; (b) how many federal, provincial and territorial sport ministerial conference calls have been held, and, for each, what were the details, including (i) the date, (ii) the agenda, (iii) whether safety and integrity in sport were on the agenda, (iv) what specifically was discussed regarding safety in sport in each of the conference calls; (c) what intergovernmental goals have been developed to address abuse, discrimination and harassment in sport in the areas of (i) awareness, (ii) policy, (iii) prevention, (iv) reporting, (v) management, (vi) monitoring; (d) what intergovernmental actions have been taken in the areas of (i) awareness, (ii) policy, (iii) prevention, (iv) reporting, (v) management, (vi) monitoring; (e) what progress has been made on mechanisms to report and monitor incidents of abuse, discrimination, and harassment (i) federally, (ii) by each province and territory; and (f) what outcomes have been achieved as a result of signing the declaration?

Questions Passed as Orders for Returns  With regard to the Dimensions program: (a) what is the size of the current team that leads the program; (b) what are the details of the team that leads the program, including (i) the name of all the positions of the current team, (ii) whether any positions have been cut since its inception, (iii) the dates for any positions that were cut; (c) what are the details of the program’s financing, including (i) the cost to administer the program annually, (ii) whether there have been any financial cuts to the program since its inception, (iii) the dates of any cuts, if any; (d) what are all of the accomplishments of the program since its inception; (e) what third-party international organizations have recognized the program since its inception; and (f) what are the details of any external reviews of the program, including (i) the start date of the review, (ii) the end date of the review, (iii) who led the review, (iv) the structure of the review, (v) who specifically was consulted in the review, including, but not limited to, the Chief Science Advisor, granting councils, research networks, research organizations, and all researchers or experts?

Questions on the Order Paper  With regard to national sport organizations (NSOs) with contribution agreements with Sport Canada (SC), and that have or had non-disclosure agreements (NDAs) with employees and coaches: (a) is SC monitoring which NSOs have NDAs with employees and coaches; (b) for each NSO, what are the details of each NDA, broken down by the year or years in place; and (c) for each NSO in (a), has the agreement ever been used, and, if so, when, and for what purpose?

Questions on the Order Paper  With regard to national sport organizations (NSOs) with contribution agreements with Sport Canada (SC), and that have or had non-disclosure agreements (NDAs) with athletes: (a) is SC monitoring which NSOs have NDAs with athletes; (b) for each NSO, what are the details of each NDA, broken down by the year or years in place; and (c) for each NSO in (a), has the agreement ever been used, and, if so, when, and for what purpose?

Sports  Mr. Speaker, safe sport should always be the primary goal of every sport, ahead of winning games, tournaments or medals, because athletes only get one childhood. Athletes should look forward to practice, going to the gym and being on the field or on the rink. They should look forward to being physically fit, being trained by coaches committed to developing good athletes and good people, having fun around other athletes and sharing the love of sport with family and friends.

Committees of the House  Mr. Speaker, I am honoured to present, in both official languages, the second report of the Standing Committee on Science and Research in relation to the motion adopted on Tuesday, February 1, 2022, regarding top talent, research and innovation. Pursuant to Standing Order 109, the committee requests that the government table a comprehensive response to this report.

Pandemic Day Act  Madam Speaker, I rise today to speak to Bill C-209, which was introduced by Senator Marie-Françoise Mégie and which seeks to designate March 11 as pandemic observance day to commemorate the efforts Canadians have made and continue to make to get through the COVID-19 pandemic. I want to take this opportunity, first, to thank the senator for developing this bill and, next, to thank my colleague for Vancouver Centre for presenting the bill in the House of Commons.

Human Rights in Iran  Mr. Speaker, freedom rallies are taking place around the world to protest the death of Mahsa Amini who went to visit relatives with her family, just like we would do. Instead of receiving a warm embrace from loved ones, she was stopped by the so-called “morality police”, taken into custody and beaten.

Her Late Majesty Queen Elizabeth II  Mr. Speaker, I rise with a very heavy heart and much sadness to pay tribute to Her Majesty Queen Elizabeth II, who committed and dedicated her life to selfless duty and service. I also hold in my thoughts King Charles III, the Queen Consort and the royal family, who are not only grieving the loss of their Queen, but also their mother, grandmother and great-grandmother.